Human Psychopharmacology: Clinical and Experimental
July 1, 2015
Giulia Francesconi, Laura Orsolini, Duccio Papanti et al.
22 citations
INTRODUCTION: Venlafaxine is one of the most frequently prescribed antidepressants worldwide, despite its toxicity risk in overdose. Furthermore, the molecule has been recently identified at the EU-wide level as one of the novel psychoactive substances. This paper aims at investigating the potential of misuse, taking into account both the existing literature and the analysis of the misusers'...
Behavioural Pharmacology
September 1, 2014
María Pilar García-pardo, Marta Rodrı́guez-arias, Concepción Maldonado et al.
29 citations
Exposure to social defeat stress increases the rewarding effects of psychostimulants in animal models, but its effect on 3,4-methylenedioxymethylamphetamine (MDMA) reward has received little attention. In the present study, we evaluated the influence of social defeat on the rewarding effects of MDMA in adolescent [postnatal day (PND) 29-40] and adult (PND 50-61) male mice using the conditioned...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
January 3, 2014
Brittney M Cox, Mrudang M Shah, Teri Cichon et al.
Adolescents and young adults disproportionately abuse 3,4-methylenedioxymethamphetamine (MDMA; 'Ecstasy'); however, since most MDMA research has concentrated on adults, the effects of MDMA on the developing brain remain obscure. Therefore, we evaluated place conditioning to MDMA (or saline) during late adolescence and assessed anxiety-like behavior and monoamine levels during abstinence. Rats...
Folia biologica
2014
S Karimi, M Jahanshahi, M J Golalipour
Ecstasy or MDMA as a psychoactive drug and hallucinogen is considered one of the most commonly used drugs in the world. This psychotropic substance is discussed both as sexually stimulating and reducing fear and anxiety. Amphetamines also destroy neurons in some brain areas. The aim of this study was to investigate the effects of MDMA on anxiety and apoptosis of hippocampal neurons. Forty-two...
Brazilian Journal of Medical and Biological Research
September 4, 2013
V. Ferraz-De-Paula, D. Stankevicius, A. Ribeiro et al.
10 citations
Anxiolytic and anxiogenic-like behavioral outcomes have been reported for methylenedioxymethamphetamine (MDMA or ecstasy) in rodents. In the present experiment, we attempted to identify behavioral, hormonal and neurochemical outcomes of MDMA treatment to clarify its effects on anxiety-related responses in 2-month-old Balb/c male mice (25-35 g; N = 7-10 mice/group). The behavioral tests used...
Journal of Psychopharmacology
February 1, 2010
G. Bedi, NT Van Dam, J. Redman
Although previous studies have examined anxiety and depression in ecstasy (±3,4-methylenedioxymethamphetamine; MDMA) users, it remains unclear whether symptoms are associated specifically with ecstasy or with polydrug use in general. We compared mean symptomatology and clinically significant symptoms in 45 ecstasy polydrug, 48 cannabis polydrug and 40 legal drug users, who completed...
Clínica y Salud
2010
Lisa Wood, Barkus Emma
1 citation
Aims: The relationship between ecstasy and affective psychological symptoms are still subject to debate. We aimed to examine the relationship between Ecstasy use and self-report depression, anxiety and schizotypy. Design: Data were collected via structured remote self-report questionnaires. Participants: Participants were split into three groups: a control group with no ecstasy use, a light...
Journal of Psychopharmacology
March 9, 2009
P.-ø. Johansen, Ts Krebs
98 citations
Abstract Exposure therapy is known to be an effective treatment for anxiety disorders. Nevertheless, exposure is not used as much as it should be, and instead patients are often given supportive medications such as serotonin reuptake inhibitors (SSRIs) and benzodiazepines, which may even interfere with the extinction learning that is the aim of treatment. Given that randomized controlled trials...
Behavioural Brain Research
May 16, 2008
V Ludwig, Y Mihov, R K W Schwarting
Using the elevated plus-maze (EPM), Wistar rats can be distinguished into high (HA) or low anxiety (LA) subjects. These differences seem to reflect traits, since HA and LA rats vary also in other anxiety-dependent tasks, neurochemical mechanisms, and psychopharmacological reactivity, including lasting consequences after single treatment with 3,4-methylenedioxymethamphetamine (MDMA). Here, we...
Journal of Psychopharmacology
August 22, 2007
Rüssel S. Falck, Jichuan Wang, Robert G. Carlson
45 citations
Research suggests that methylenedioxymethamphetamine (MDMA)/`ecstasy' can cause serotonin depletion as well as serotonergic neurodegradation that may result in depression. This longitudinal study used the Beck Depression Inventory (BDI-II) to assess depressive symptomatology every six months over a two-year period among a community sample of young adult MDMA/`ecstasy' users ( n = 402)....